← Back to Search

Monoclonal Antibodies

Experimental for Liver Cancer

Phase 1 & 2

Waitlist Available

Led By Nabeel Badri

Research Sponsored by University of Rochester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 10 years

Awards & highlights

Study Summary

This trialtests a new combination therapy for unresectable or metastatic liver cancer to see if it's safe and effective.

Eligible Conditions

Liver Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Trial Design

1Treatment groups

Experimental Treatment

Group I: ExperimentalExperimental Treatment1 Intervention

Open label safety and tolerability assessment of PXS-5505: (PXS-5505) 100-200mg BID (Atezolizumab) 1200mg every 3 weeks (Bevacizumab) 15mg/kg every 3 weeks

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor

842 Previous Clinical Trials

534,038 Total Patients Enrolled

Nabeel BadriPrincipal InvestigatorUniv. of Rochester Wilmot Cancer Center

1 Previous Clinical Trials

25 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what illnesses can Experimental be used to provide relief?

"Non-small cell lung carcinoma is traditionally managed with Experimental. It can also be a viable treatment for postoperative, recurrent non-squamous non-small cell lung cancer, and recurrence of platinum-sensitive epithelial ovarian cancer."

Answered by AI

Are there any past attempts to evaluate the efficacy of Experimental?

"Currently, 621 studies are underway for Experimental with 142 of them in the late stages. While Taibei, Taiwan is a major research hub for this drug, there are over 30 000 trial sites being used globally."

Answered by AI

Are any fresh participants being added to this experiment?

"Affirmative. According to the information hosted on clinicaltrials.gov, this medical experiment is presently in search of participants and was first published on September 20th 2022. The trial has since been updated on November 3rd with the aim of recruiting 48 people across a single location."

Answered by AI

What is the ceiling for participation in this experiment?

"Indeed, the information available on clinicaltrials.gov shows that this research is actively recruiting participants. This study was initially published on September 20th 2022 and has been recently amended on November 3rd of the same year. It requires 48 volunteers from a single location to complete it successfully."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Nabeel Badri 2022. "Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05109052.